

- **Name:** Gerald S. Falchook
 - **Current Position & Affiliation:** Director, Drug Development, Sarah Cannon Research Institute at HealthONE
 - **Country:** US
-

- **Educational Background:**

- **Degree-Granting Education**

- Rice University, Houston, TX, BA, 1997, Biochemistry, Biology, History

- Louisiana State University School of Medicine, New Orleans, LA, MD, 2001, Medicine

- University of Texas Health Science Center Graduate School of Biomedical Sciences, Houston, TX, MS, 2009, Cancer Biology

- **Professional Experience:**

- **Academic Appointments**

- Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2008-6/2014

- Associate Member of the Graduate Faculty, Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, 2/2013-6/2014

- **Administrative Appointments/Responsibilities**

- Co-director, ICT Clinical Studies Meeting, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-6/2014

- Associate Medical Director, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Clinical Translational Research Center (CTRC), Houston, TX, 9/2012-6/2014

- **Other Appointments/Responsibilities**

- Attending, Internal Medicine Outpatient Clinic, San Diego Veterans Affairs Healthcare System, JC Nationwide, San Diego, CA, 8/2004-12/2004

- Attending, Internal Medicine Hospitalist, Exempla Good Samaritan Medical Center, Kaiser Permanente Medical Group, CompHealth, Lafayette, CO, 1/2005-5/2005

- Inpatient Liaison, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2008-6/2014

Committee Member, Scientific Program Committee, Developmental Therapeutics - Clinical and Experimental Pharmacology Track, American Society of Clinical Oncology (ASCO), Alexandria, VA, 6/2013-present

Committee Member, Scientific Program Committee, Developmental Immunotherapy Therapeutics - American Society of Clinical Oncology (ASCO), Alexandria, VA, 2019-2022

• **Professional Organizations:**

Professional Society Activities, with Offices Held

National and International

American Society of Clinical Oncology

Member, 2005-present

American Association for Cancer Research, Philadelphia, PA

Member, 5/2013-present

American College of Physicians-American Society of Internal Medicine

Member, 1997-2006

• **Main Scientific Publications:**

1. Papadopoulos KP, Lakhani N, Falchook GS, Riley G, Xu J, Baeck J, Gordon G, Trehu E, Wang JS. Phase 1, First-In-Human Trial Evaluating the Safety and Tolerability of Programmed Cell Death Receptor-1 (PD-1) Inhibitor, JTX-4014, in Adult Patients with Advanced, Refractory, Solid Tumor Malignancies. *Journal for Immunotherapy of Cancer (JITC)*. Submitted.
2. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemester FB, Falchook GS, Karp DD, Wheeler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Activity of the HDAC inhibitor vorinostat and mTOR inhibitors sirolimus or everolimus in patients with treatment refractory Hodgkin lymphoma. *Blood Cancer Discovery*, 2020. Submitted.
3. Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook GS, Hong DS, Girard P, El Bawab S. Translational Pharmacokinetic-pharmacodynamic Modelling of Preclinical and Clinical Data of Oral MET Inhibitor Tepotinib to Determine the Recommended Phase II Dose. *Clinical Pharmacology & Therapeutics*, 2020. Submitted.
4. Patel MR, Falchook GS, Hamada K, Makris L, Bendell J. A Phase II Trial of Trifluridine/Tipiracil Plus Nivolumab in Patients with Heavily Pretreated Microsatellite-Stable Metastatic Colorectal Cancer. *Cancer Medicine*, 2020. Submitted.